SK Biopharmaceuticals to Present Key Cenobamate Data at American Academy of Neurology Meeting

SK Biopharmaceuticals’ US subsidiary, SK Life Science, announced that it will present multiple posters at the 2026 American Academy of Neurology (AAN) Annual Meeting, which will be held in Chicago, Illinois, from April 18 to April 22.

SK Life Science will present clinical results, real-world evidence (RWE), pharmacokinetic data, and long-term efficacy data for cenobamate—an innovative anti-epileptic drug (marketed in the US as XCOPRI®)—during the event. Additionally, the company will share an in-depth analysis of real treatment experiences and communication barriers faced by people with epilepsy and healthcare professionals.

In particular, the company will unveil new methodological analysis results from the survey “Hope, Hesitation, and Hard Truths,” which deeply explores communication gaps between people with epilepsy and healthcare professionals. This survey was designed to examine perception differences between people with epilepsy and healthcare professionals, and was first released in November of last year during “Epilepsy Awareness Month.” The upcoming presentation will feature detailed analyses of the survey design and respondent groups, as well as additional insights reflecting the perspectives of various stakeholders.

Sunita Misra, Chief Medical Officer of SK Life Science, explained, “Understanding the communication gap between patients and healthcare professionals is crucial to improving the quality of epilepsy care.”

She added, “The ‘Hope, Hesitation, and Hard Truths’ survey provides valuable insights into the experiences of various stakeholders involved in epilepsy care, including patients, neurologists and epileptologists, and advanced practice providers (APPs). By considering these diverse perspectives, we can better understand the barriers within the clinical process and identify communication gaps that may influence patient management and decision-making.”

Meanwhile, SK Life Science will present a total of 10 posters at this meeting, covering the clinical outcomes, real-world evidence (RWE), and pharmacokinetic characteristics of cenobamate. All abstracts presented at the American Academy of Neurology meeting can be found on the official AAN website.

This content was produced with the assistance of AI translation services.